Get the Stockscreener App
83.87
0.97%
-0.82
After Hours:
83.50
-0.37
-0.44%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca PLC stock is traded at $83.87, with a volume of 5.02M.
It is down -0.97% in the last 24 hours and up +9.95% over the past month.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$84.69
Open:
$84.86
24h Volume:
5.02M
Relative Volume:
1.01
Market Cap:
$260.11B
Revenue:
$56.53B
Net Income/Loss:
$8.32B
P/E Ratio:
31.50
EPS:
2.6622
Net Cash Flow:
$8.49B
1W Performance:
-0.76%
1M Performance:
+9.95%
6M Performance:
+24.09%
1Y Performance:
+7.17%
1-Day Range:
$83.78
$85.18
1-Week Range:
$83.09
$85.18
52-Week Range:
$61.24
$86.57
Astrazeneca PLC Stock (AZN) Company Profile
Name
Astrazeneca PLC
Sector
Industry
Phone
44 20 3749 5000
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Compare AZN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
83.87 | 262.58B | 56.53B | 8.32B | 8.49B | 2.6622 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca PLC Stock (AZN) Latest News
Will AstraZeneca PLC (ZEG) stock profit from AI boomGap Up & Low Risk High Win Rate Stock Picks - newser.com
How AstraZeneca PLC (Common Stock) (ZEGA) stock performs during market turbulence2025 Geopolitical Influence & Detailed Earnings Play Alerts - newser.com
Will AstraZeneca PLC (ZEG) stock test record highs in 2025Weekly Risk Summary & Weekly Setup with High ROI Potential - newser.com
Has AstraZeneca PLC Depositary Receipt formed a bullish divergence2025 Price Action Summary & Long-Term Growth Plans - newser.com
Will Precidian ETFs Trust AstraZeneca PLC stock hit Wall Street targetsPortfolio Return Report & Free Accurate Trade Setup Notifications - newser.com
Is AstraZeneca PLC Depositary Receipt meeting your algorithmic filter criteriaPortfolio Value Summary & Long-Term Growth Plans - newser.com
Top Research Reports for AstraZeneca, RTX & Applied Materials - sharewise.com
Risk vs reward if holding onto AstraZeneca PLC Depositary Receipt2025 EndofYear Setup & AI Enhanced Execution Alerts - newser.com
AstraZeneca, Gilead vie for edge in race to treat tough breast cancer - The Economic Times
Why ETFs are accumulating AstraZeneca PLC (ZEG) stockPortfolio Profit Report & Real-Time Volume Trigger Notifications - newser.com
Why AstraZeneca PLC (ZEG) stock stays on buy listsMarket Risk Summary & Proven Capital Preservation Methods - newser.com
ESMO 25: AstraZeneca And Lilly Turn Up Heat In FRa Antibody-Drug Conjugates - Citeline News & Insights
Can AstraZeneca PLC Depositary Receipt stock sustain revenue growth2025 Pullback Review & Low Risk Growth Stock Ideas - newser.com
AstraZeneca, Daiichi’s Datroway excels in hard-to-treat breast cancer - BioPharma Dive
Is AstraZeneca PLC (Common Stock) (ZEGA) stock inflation resilientOil Prices & Community Verified Trade Signals - newser.com
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock - sharewise.com
AstraZeneca PLC Depositary Receipt stock momentum explainedQuarterly Portfolio Summary & Growth-Oriented Investment Plans - newser.com
AstraZeneca receives positive CHMP opinion for subcutaneous Saphnelo in EU - Investing.com
Is AstraZeneca PLC Depositary Receipt stock ready for a breakout - newser.com
US FDA OKs Tezspire in CRSwNP, expanding AstraZeneca’s label beyond asthma - Stock Titan
AZN wins EU CHMP support for once-weekly SC Saphnelo; 40,000 patients treated - Stock Titan
Astra, Gilead Vie for Edge in Race to Treat Tough Triple-Negative Breast Cancer - Bloomberg.com
How to build a custom watchlist for AstraZeneca PLC Depositary ReceiptJuly 2025 Recap & High Accuracy Investment Entry Signals - newser.com
Prediction: This Unstoppable Vanguard ETF Will Beat the S&P 500 Again in 2026 - The Motley Fool
Can Precidian ETFs Trust AstraZeneca PLC stock deliver double digit returns2025 Top Decliners & Real-Time Price Movement Reports - nchmf.gov.vn
AstraZeneca presents 'major results' for Datroway in breast cancer - MarketScreener
Will AstraZeneca PLC (ZEG) stock benefit from Fed rate cuts2025 Performance Recap & Reliable Intraday Trade Plans - newser.com
Pattern recognition hints at AstraZeneca PLC Depositary Receipt upsideProfit Target & Trade Opportunity Analysis - newser.com
REGAstraZeneca PLCUS FDA Approves Tezspire in CRSwNP - TradingView
AstraZeneca and Daiichi’s drug Enhertu raises hopes for early breast cancer cure - Mint
AstraZeneca and Daiichi’s Drug Enhertu Raises Hopes for Early Breast Cancer Cure - Bloomberg.com
Why AstraZeneca PLC Depositary Receipt stock remains undervaluedGDP Growth & Weekly High Conviction Trade Ideas - newser.com
AstraZeneca, Daiichi Sankyo's Early Breast Cancer Drug Shows Positive Results in Late-stage Trial - MarketScreener
AstraZeneca, Daiichi Sankyo Report Positive Results from Phase 3 Trial of Datroway - MarketScreener
AstraZeneca (AZN) Reports Success in Breast Cancer Trial with En - GuruFocus
AstraZeneca (AZN) Reports Promising Results in Breast Cancer Tri - GuruFocus
AstraZeneca's Datroway extends survival in aggressive breast cancer - Reuters
AstraZeneca, Amgen Secure US FDA Nod for CRSwNP Treatment - MarketScreener
AstraZeneca PLC Depositary Receipt recovery potential after sell offQuarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Bre - GuruFocus
Will AstraZeneca PLC Depositary Receipt stock gain from strong economyGap Up & Long Hold Capital Preservation Plans - nchmf.gov.vn
Why global investors buy AstraZeneca PLC (Common Stock) (ZEGA) stockJuly 2025 Intraday Action & Stepwise Swing Trade Plans - nchmf.gov.vn
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment - Reuters
Astrazeneca says positive results from Destiny-Breast11 Phase III trial - MarketScreener
Can AstraZeneca PLC (ZEG) stock reach $200 price target2025 Earnings Impact & Weekly Stock Breakout Alerts - nchmf.gov.vn
How to monitor AstraZeneca PLC Depositary Receipt with trend dashboardsWeekly Volume Report & AI Forecast for Swing Trade Picks - newser.com
Block Trades: Why AstraZeneca PLC Depositary Receipt stock remains undervalued2025 Pullback Review & Stock Timing and Entry Methods - nchmf.gov.vn
Astrazeneca PLC Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):